Abstract:Xu Zuo, 1 Yinuo Gu, 1 Xiaoping Guo, 1 Wenxue Zheng, 1 Haoyu Zheng, 1 Yiming An, 1 Caina Xu, 2, 3 Fang Wang 1, 3 1 Department of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, People's Republic of China; 2 Department of Biochemistry, College of Basic Medical Sciences, Jilin University, Changchun, 130021, People's Republic of China; 3 Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, People's Republic of China Correspondence: Caina Xu; Fang Wang, Email ; Purpose: Inhaled corticosteroids, including budesonide (BUD), are widely employed for the treatment of asthma. However, the frequent use of corticosteroids is associated with numerous adverse effects and poses challenges to ongoing drug therapy and patient adherence. Budesonide liposomal nanoparticles (BUD-LNPs) were developed to improve the bioavailability of the drug and thereby improve the effectiveness of asthma treatment. Methods: BUD-LNPs were prepared via thin-film hydration, and the characterizations, stability, and in vitro release of BUD-LNPs were studied. In vitro cellular uptake was observed by laser-scanning confocal microscope (LSCM) and flow cytometry. And the in vitro anti-inflammatory activity of BUD-LNPs was evaluated by measuring the expression of pro-inflammatory cytokines in activated macrophages. Besides, the accumulation time in the lung of drugs delivered via liposomal carriers and free drugs was compared in vivo. And the in vivo therapeutic efficacy of BUD-LNPs was assessed in OVA-induced asthmatic mice. Finally, in vivo biosafety assessment was performed. Results: The particle size, PDI, and zeta potential of BUD-LNPs were 127.63± 1.33 nm, 0.27± 0.02, and 3.33± 0.13 mV, respectively. BUD-LNPs exhibited excellent biosafety and anti-inflammatory activity in vitro. Furthermore, compared with the free drugs, the utilization of liposomal nano-vehicles for drugs delivery could effectively extend the duration of drugs accumulation in the pulmonary system. Additionally, treatment with BUD-LNPs alleviated airway hyperresponsiveness, reduced airway mucus secretion, and mitigated pulmonary inflammation in OVA-induced asthmatic mice. And the BUD-LNPs demonstrated superior therapeutic efficacy compared to free BUD. Conclusion: BUD-LNPs was successfully prepared with excellent stability and sustained release for 24 h in vitro. The data of anti-inflammatory activity, asthma therapeutic effects and safety studies indicated that drug delivery mediated by liposomal nano-vehicles was a feasible and desirable strategy for medical strategy and showed great promise in the clinical therapy of asthma. Keywords: liposomal nanoparticles, asthma, budesonide, pulmonary delivery, nano-vehicles Asthma is a widely prevalent chronic and heterogeneous ailment affecting individuals of all ages, characterized by the presence of airway hyperresponsiveness, mucus hypersecretion, and chronic inflammation. 1 This condition is often accompanied by distressing symptoms including dyspnea, wheezing, coughing, and chest tightness, with severe cases potentially posing life-threatening risks. 2 The incidence and progression of asthma are influenced by a multitude of factors, including genetic predisposition and environmental conditions. Consequently, there has been a steady rise in the prevalence of asthma, with an estimated global population of approximately 400 million individuals affected by the condition by the year 2025. 3 Despite inhaled corticosteroids are the mainstay of asthma treatment, the current short-acting formulations require frequent administration. 4,5 The endeavor to diminish dosing frequency by augmenting the dosage would result in an initial escalation in drug concentration succeeded by a swift decline, thereby presenting obstacles to both sustained pharmacotherapy and patient compliance. 6 Hence, there is a pressing need for novel therapeutic interventions to effectively manage symptoms and exacerbations in individuals suffering from asthma. Budesonide (BUD), a glucocorticoid exhibiting potent anti-inflammatory properties and minimal systemic impact, holds promise as a viable pharmaceutical option for managing asthma, allergic rhinitis, and esophagitis. 7,8 Nevertheless, the practical insolubility of BUD in water poses certain constraints on its inhalation-based administration, including the presence of a protective mucosal layer, sustained mucociliary clearance, and limited residence time of the formulation within the nasal cavity or airways. 9 Nanotechnology offered a compelling strategy -Abstract Truncated-

Preparation, in Vitro and in Vivo Evaluation of Budesonide Loaded Core/shell Nanofibers As Oral Colonic Drug Delivery System.

Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment

Preparation and Characterization of a Novel Multiparticulate Dosage Form Carrying Budesonide-Loaded Chitosan Nanoparticles to Enhance the Efficiency of Pellets in the Colon

Preparation and Characterization of Budesonide-Loaded Solid Lipid Nanoparticles for Pulmonary Delivery

Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis

Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model

Caffeic Acid-Conjugated Budesonide-Loaded Nanomicelle Attenuates Inflammation in Experimental Colitis

Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization

Reactive oxygen species-scavenging hollow MnO2 nanozymes as carriers to deliver budesonide for synergistic inflammatory bowel disease therapy

Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression

Design, Development and In vivo Evaluation of Core in Cup Tablets of Budesonide

Nanoporous CD-MOF particles with uniform and inhalable size for pulmonary delivery of budesonide.

Modeling the Molecular Interactions of Budesonide with Bovine Serum Albumin Guides the Rational Preparation of Nanoparticles for Pulmonary Delivery

Preparation of budesonide–dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis

Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis

The Role of Nanoparticle Morphology on Enhancing Delivery of Budesonide for Treatment of Inflammatory Bowel Disease

Preparation of Budesonide-Loaded Liposomal Nanoparticles for Pulmonary Delivery and Their Therapeutic Effect in OVA-Induced Asthma in Mice

Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis

A novel and simple oral colon-specific drug delivery system based on the pectin/modified nano-carbon sphere nanocomposite gel films

A nanofiber-based drug depot with high drug loading for sustained release

Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases